Please ensure Javascript is enabled for purposes of website accessibility

Why Sarepta Therapeutics Inc. Is Up Big Today

By Brian Feroldi - Apr 28, 2016 at 2:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A bullish article suggesting that eteplirsen may still have a chance at winning an accelerated FDA approval sends shares higher.

IMAGE SOURCE: TBIT ON PIXABAY.

What: Shares of biotech stock Sarepta Therapeutics (SRPT 5.58%) are surging more than 26% higher as of 1:15 p.m. ET after a bullish article by TheStreet.com's Adam Feurstein suggests that the company's Duchenne muscular dystrophy (DMD) drug eteplirsen may still have a chance at winning Food and Drug Administration approval.

So what: The article makes a convincing case that Dr. Janet Woodcock, the FDA's most senior evaluator, may be willing to go against the committee's recommendation and give eteplirsen the green light. That may not be as far-fetched as it sounds as the committee's vote against an accelerated approval was quite close. Six members of the panel were in favor of it while seven voted against it. 

In the article, Feurstein highlighted several comments that Woodcock and a few other influential physicians made during the meeting, which suggests that eteplirsen isn't as much of a guaranteed denial as many investors expect. 

Sarepta Therapeutics traders appear to be convinced that the article brings up a handful of valid points, hence the shares are skyrocketing today.

Now what: While it still looks like the most likely outcome is a rejection, it is possible that the FDA could surprise investors and the DMD community at large with an approval. After all, eteplirsen is the last drug standing as a potential treatment for DMD after the agency outright rejected BioMarin Pharmaceuticals(BMRN 2.33%) drug drisapersen in January. That leaves patients with DMD no real treatment options, which is a point not lost on the agency. For that reason, the FDA could be willing to overlook the fact that Sarepta's clinical trial only included 12 patients.

However, if history is any guide, Sarepta's chances of approval still seem quite low as the FDA did follow the advice of the advisory committee when it voted on whether to approve BioMarin's drug. Either way, investors won't have to wait long to get an official ruling as the agency is set to make its decision on May 26.

While this article does a great job of making a case that the drug still has a chance, I think there's too much uncertainty in the air for me to consider making an investment. For that reason, I'm content to continue watching this fascinating story unfold from the sidelines. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$71.30 (5.58%) $3.77
BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
BMRN
$79.12 (2.33%) $1.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.